Intio, Inc.

INTIO's focus is on all interventional oncologic therapies including surgery, ablation, chemoembolization or radioembolization, and palliation for pain or relief of obstructions. INTIO is committed to developing software tools for planning, image guidance and quantitative image analysis for the interventional oncology market. Whether cancer patients are treated by systemic, local or regional therapies, INTIO has solutions that aid the physician planning, treating and assessing the effectiveness of the particular therapy being used to treat the patient's cancer. The INTIO ClearStart SVM(TM) Segmentation and Volumetric Measurement system received FDA 510(k) clearance in December 2011 for applications in lung, liver, and lymph node lesions.

• Employees5
• Founded2005
• Annual Revenue$7833000
• Total Funding$8100000